Identifying Disparities in Mild Cognitive Impairment and Alzheimer's Disease and Related Dementias in Diverse Prostate Cancer Survivors

确定不同前列腺癌幸存者的轻度认知障碍和阿尔茨海默病及相关痴呆症的差异

• 批准号: 10713284
• 负责人: Brian D Gonzalez
• 金额: $ 32.72万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-23 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10713284
• 关键词: Address; African American; Alzheimer' s disease diagnosis; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Area; Award; Benefits and Risks; Cancer Patient; Cancer Survivor; Cancer Survivorship; Clinical; Cognitive; Complement; Data; Data Set; Decision Making; Dementia; Disparity; Distress; Education; Educational Status; Employment Status; Ensure; Equity; Ethnic Origin; Hispanic; Household; Impaired cognition; Income; Individual; Knowledge; Malignant Neoplasms; Malignant neoplasm of prostate; Measures; Meta-Analysis; Methodology; Not Hispanic or Latino; Outcome; Paper; Parents; Participant; Patient Education; Patient Self-Report; Patients; Persons; Prevention; Prostate Cancer therapy; Psychosocial Assessment and Care; Public Health; Race; Reporting; Research; Risk; Risk Factors; Risk Reduction; Sampling; Scoring Method; Statistical Methods; Surveys; Symptoms; androgen deprivation therapy; cognitive function; cohort; deprivation; ethnic diversity; ethnic minority; genetic risk factor; health disparity; high risk; improved; indexing; large datasets; men; mild cognitive impairment; neighborhood disadvantage; prostate cancer survivors; psychosocial; racial diversity; racial minority; recruit; social health determinants

PROJECT SUMMARY/ABSTRACT Mild cognitive impairment is common among people with cancer and is often a precursor to Alzheimer’s and related dementias. Recent research has focused on risk of mild cognitive impairment in prostate cancer survivors, including among patients receiving androgen deprivation therapy. For example, a recent meta-analysis found androgen deprivation therapy recipients had higher odds of dementia than controls. However, previous studies have not examined social determinants of health disparities as risk factors for mild cognitive impairment or dementia in prostate cancer. This is a significant public health issue because prostate cancer is the most common malignancy in US men and most prostate cancer patients are prescribed androgen deprivation therapy. To address this gap, this study will leverage the parent award study recruiting a diverse cohort of 250 African American, 250 Hispanic, and 250 non-Hispanic White prostate cancer survivors. This cohort overcomes limitations in the rigor of prior research that had relatively small samples of racial/ethnic minority prostate cancer survivors. All participants in the cohort will be asked to complete a validated survey of cognitive function. We conservatively estimate 200 participants in each group will join the supplement study. This will enable us to identify social determinants of health risk factors for mild cognitive impairment in prostate cancer survivorship. These risk factors will include race/ethnicity, neighborhood disadvantage measured using the Area Deprivation Index, household income, education level, and employment status. This supplement will also enable us to examine social determinants of health disparities in risk of mild cognitive impairment after receiving androgen deprivation therapy for prostate cancer. Because mild cognitive impairment is often a precursor to Alzheimer’s disease and related dementias, we will also aim to replicate these findings in a large dataset with over 1,000,000 racially and ethnically diverse prostate cancer survivors. This will enable us to identify disparities in risk of diagnosis of Alzheimer’s disease or related dementia in prostate cancer survivors, including after receiving androgen deprivation therapy. The parent award study does not currently examine any cognitive outcomes. Instead, the parent award study examines disparities and risk factors for symptom burden among PC survivors. This study complements the parent award by examining disparities in mild cognitive impairment and Alzheimer’s disease and related dementias. This study’s specific aims are to identify, among prostate cancer survivors, social determinants of health disparities in risk of 1) mild cognitive impairment, 2) mild cognitive impairment after receiving androgen deprivation therapy, and 3) Alzheimer’s disease or related dementia. This study will contribute to reducing risk of mild cognitive impairment and Alzheimer’s disease and related dementias and will improve informed decision- making and education on risks/benefits of androgen deprivation therapy for prostate cancer survivors.

项目摘要/摘要 轻度认知障碍在癌症患者中很常见，通常是阿尔茨海默氏症和 相关痴呆症。最近的研究集中于前列腺癌的轻度认知障碍风险 幸存者，包括接受雄激素剥夺疗法的患者。例如，最近的荟萃分析 发现雄激素剥夺治疗接受者的痴呆几率高于对照。但是，以前 研究尚未检查社会决定者的健康差异作为轻度认知障碍的风险因素 或前列腺癌的痴呆症。这是一个重大的公共卫生问题，因为前列腺癌是最大的 我们的男性和大多数前列腺癌患者的常见恶性肿瘤是处方雄激素剥夺疗法的。 为了解决这一差距，这项研究将利用父母奖研究招募250名非洲潜水员队列 美国，250个西班牙裔和250个非西班牙裔白人前列腺癌存活。这个队列克服了 先前研究严格的局限 幸存者。所有队列中的所有参与者都将被要求完成对认知功能的验证调查。我们 保守地估计每个小组的200名参与者将加入补充研究。这将使我们能够 在前列腺癌生存中确定健康危险因素的社会决定者。 这些风险因素将包括种族/民族，使用该地区剥夺测量的邻里灾难 指数，家庭收入，教育水平和就业状况。这种补充剂也将使我们能够 检查社会决定者在接受雄激素后轻度认知障碍风险的健康差异 前列腺癌的剥夺疗法。因为轻度的认知障碍通常是阿尔茨海默氏症的先驱 疾病和相关痴呆症，我们还将在一个超过1,000,000的大数据集中复制这些发现 种族和种族种植的前列腺癌存活。这将使我们能够确定有风险的差距 诊断前列腺癌存活中阿尔茨海默氏病或​​相关痴呆症，包括接受 雄激素剥夺疗法。 父母奖研究目前尚未检查任何认知结果。相反，父母奖研究 检查PC存活中症状燃烧的分布和危险因素。这项研究符合 通过检查轻度认知障碍和阿尔茨海默氏病的分布以及相关的父母奖 痴呆症。这项研究的具体目的是在前列腺癌的存活中确定社会决定者 1）轻度认知障碍的健康差异，2）接受雄激素后轻度认知障碍 剥夺疗法和3）阿尔茨海默氏病或​​相关痴呆症。这项研究将有助于降低风险 轻度认知障碍和阿尔茨海默氏病和相关痴呆症，将改善明智的决策 - 对前列腺癌存活的雄激素剥夺疗法的风险/益处进行教育。